An open-label trial of memantine for the treatment of posttraumatic stress disorder
- Conditions
- posttraumatic stress disorder
- Registration Number
- JPRN-jRCTs031180200
- Lead Sponsor
- Kim Yoshiharu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
(1) Patients diagnosed with posttraumatic stress disorder
(2) Patients who are attending the National Center of Neurology and Psychiatry Hospital or collaborative institutes
(3) Individuals who can understand the nature of this study and provide informed consent
(1) Patients with duration of illness less than 6 months
(2) Individuals who received specific psychotherapy (e.g., prolonged exposure therapy, cognitive processing therapy, and eye movement desensitization and reprocessing therapy) within 3 months prior to the recruitment into the study
(3) Patients with comorbid schizophrenia, severe manic phase of bipolar disorder, or intellectual disability
(4) Individuals with serious suicidal ideation
(5) Individuals with severe physical illnesses that can interfere with study participation
(6) Pregnant women
(7) Individuals with the following physical conditions that are described in manufacturer's package insert as careful administration:
-History of epilepsy or convulsion
-Renal dysfunction
-Factors increasing urine pH
-Severe liver dysfunction
(8) Patients considered unqualified for the study by their attending physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PTSD diagnosis/severity (PTSD Diagnostic Scale: PDS)
- Secondary Outcome Measures
Name Time Method (1) PTSD severity (Impact of Event Scale-Revised: IES-R) <br>(2) Cognitive function (Repeatable Battery for the Assessment of Neuropsychological Status: RBANS) <br>(3) Depressive symptoms (Beck Depression Inventory-II) <br>(4) Anxiety symptoms (State-Trait Anxiety Inventory) <br>(5) Cognitive changes after traumatic events (Posttraumatic Cognitions Inventory) <br>(6) Overall symptom severity/improvement (Clinical Global Impression) <br>(7) Adverse events (UKU Side-Effect Rating Scale)